Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short versus long hydration during weekly cisplatin chemoradiation
NL-OMON21238Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cisplatin in head and neck cancer (HNC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Creatinine increased grade 2 or higher according to CTCAE v5.0 using baseline criteria. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
cisplatin
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NL-OMON21238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21238.